This study aimed to examine variation in genetic testing between neonatal intensive care units (NICUs) across hospitals over time.
We performed a multicenter large-scale retrospective cohort study using NICU discharge data from the Pediatric Hospital Information System database between 2016 and 2021. We analyzed the variation in the percentage of NICU patients who had any genetic testing across hospitals and over time. We used a multivariable multilevel logistic regression model to investigate the potential association between patient characteristics and genetic testing.
The final analysis included 207,228 neonates from 38 hospitals. Overall, 13% of patients had at least 1 genetic test sent, although this varied from 4% to 50% across hospitals. Over the study period, the proportion of patients tested increased, with the increase disproportionately borne by hospitals already testing high proportions of patients. On average, patients who received genetic testing had higher illness severity. Controlling for severity, however, only minimally reduced the degree of hospital-level variation in genetic testing.
The percentage of NICU patients who undergo genetic testing varies among hospitals and increasingly so over time. Variation is largely unexplained by differences in severity between hospitals. The degree of variation suggests that clearer guidelines for NICU genetic testing are warranted.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
ACMG Member LoginAre you an ACMG Member? Sign in for online access.
Subscribe:Subscribe to Genetics in Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Exome sequencing in neonates: diagnostic rates, characteristics, and time to diagnosis.Genet Med. 2018; 20: 1468-1471https://doi.org/10.1038/gim.2018.11
- Genome-wide sequencing in acutely ill infants: genomic medicine’s critical application?.Genet Med. 2019; 21: 498-504https://doi.org/10.1038/s41436-018-0055-z
- Making a genetic diagnosis in a level IV neonatal intensive care unit population: who, when, how, and at what cost?.J Pediatr. 2019; 213: 211-217.e4https://doi.org/10.1016/j.jpeds.2019.05.054
- Estimating the burden and economic impact of pediatric genetic disease.Genet Med. 2019; 21 (Published correction appears in Genet Med. 2019;21(9):2161): 1781-1789https://doi.org/10.1038/s41436-018-0398-5
- The effect of Mendelian disease on human health: a measurement.Am J Med Genet. 1985; 21: 231-242https://doi.org/10.1002/ajmg.1320210205
- Infant mortality: the contribution of genetic disorders.J Perinatol. 2019; 39: 1611-1619https://doi.org/10.1038/s41372-019-0451-5
- Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease: a randomized clinical trial.JAMA Pediatr. 2021; 175 (Published correction appears in JAMA Pediatr. 2021;175(12):1295): 1218-1226https://doi.org/10.1001/jamapediatrics.2021.3496
- Influence of genetic information on neonatologists’ decisions: a psychological experiment.Pediatrics. 2022; 149e2021052130https://doi.org/10.1542/peds.2021-052130
- Anticipating uncertainty and irrevocable decisions: provider perspectives on implementing whole-genome sequencing in critically ill children with heart disease.Genet Med. 2018; 20: 1455-1461https://doi.org/10.1038/gim.2018.25
- Next generation sequencing in neonatology: what does it mean for the next generation?.Hum Genet. 2022; 141: 1027-1034https://doi.org/10.1007/s00439-022-02438-9
- Genetic test availability and spending: where are we now? Where are we going?.Health Aff (Millwood). 2018; 37: 710-716https://doi.org/10.1377/hlthaff.2017.1427
- Blue shield of California becomes first health plan in U.S. to cover cost of rapid whole genome sequencing for critically ill children. Rady Children’s Institute Genomic Medicine.(Published March 13, 2020)https://radygenomics.org/2020/blue-shield-of-california-becomes-first-health-plan-in-u-s-to-cover-cost-of-rapid-whole-genome-sequencing-for-critically-ill-children/Date accessed: June 22, 2022
- Understanding and controlling variation in public health.J Public Health Manag Pract. 2012; 18: 74-78https://doi.org/10.1097/PHH.0b013e318233d5eb
- The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care.Ann Intern Med. 2003; 138: 288-298https://doi.org/10.7326/0003-4819-138-4-200302180-00007
- Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation.BMC Pediatr. 2014; 14: 199https://doi.org/10.1186/1471-2431-14-199
- Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.Genet Med. 2017; 19: 890-899https://doi.org/10.1038/gim.2016.209
- Do more hospital beds lead to higher hospitalization rates? A spatial examination of Roemer’s law.PLoS One. 2013; 8e54900https://doi.org/10.1371/journal.pone.0054900
- How neonatologists use genetic testing: findings from a national survey.J Perinatol. 2022; 42: 260-261https://doi.org/10.1038/s41372-021-01283-4
Published online: December 12, 2022
Accepted: December 8, 2022
Received in revised form: December 7, 2022
Received: September 27, 2022
© 2022 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.